VistaGen Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 40
- Market Cap
- $95.5M
- Website
- http://www.vistagen.com
- Introduction
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
A U.S. Double-blind, Placebo-controlled Phase 2 Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: Fasedienol Nasal Spray - Placebo Nasal SprayDrug: Fasedienol Nasal Spray - Fasedienol Nasal SprayDrug: Placebo Nasal Spray - Placebo Nasal Spray
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06809179
- Locations
- 🇺🇸
Vistagen Clinical Site, Cleveland, Ohio, United States
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
- Conditions
- Social Anxiety Disorder (SAD)
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06615557
- Locations
- 🇺🇸
Vistagen Clinical Site, Houston, Texas, United States
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3)
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06358651
- Locations
- 🇺🇸
Vistagen Clinical Site, Everett, Washington, United States
AV-101 Alone and in Combination With Probenecid in Healthy Subjects
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05280054
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Glendale, California, United States
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 483
- Registration Number
- NCT05030350
- Locations
- 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT05011396
- Locations
- 🇺🇸
VistaGen Clinical Center, Allentown, Pennsylvania, United States
🇺🇸VistaGen Clinical Site, Austin, Texas, United States
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 209
- Registration Number
- NCT04754802
- Locations
- 🇺🇸
VistaGen Clinical Sites, Fort Myers, Florida, United States
🇺🇸VistaGen Clinical Site, Bellevue, Washington, United States
PH94B in the Treatment of Adjustment Disorder With Anxiety
- Conditions
- Adjustment Disorder With Anxious Mood
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04404192
- Locations
- 🇺🇸
VistaGen Clinical Site, New York, New York, United States
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
- Conditions
- L-Dopa Causing Adverse Effects in Therapeutic UseDyskinesia, Medication-InducedParkinson Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04147949
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT03078322
- Locations
- 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States